5 results about "Insulin Gene" patented technology

The invention provides a product for treating type 2 diabetes mellitus based on a stem cell insulin gene vector. The product consists of mesenchymal stem cells modified by genetic engineering and a cell preservation solution, the genetic engineering modified mesenchymal stem cells are obtained by transducing human mesenchymal stem cells by using a recombinant lentiviral vector, and the recombinant lentiviral vector can express a fusion protein composed of three parts of human proinsulin, a linker peptide and a GLP-1 receptor agonist. According to the application, human proinsulin and a GLP-1 receptor agonist are constructed into a single fusion protein, human mesenchymal stem cells are transduced by utilizing a lentiviral vector, and then a standardized three-stage induced differentiation process is carried out, so that a cell therapy product which can intelligently respond to blood glucose changes for a long time and has stable functions is finally obtained. The defects of transient treatment effect, single secretion function and large cell product batch-to-batch difference in the prior art are fundamentally overcome.

A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled.

The present invention discloses a gene construct comprising a nucleotide sequence encoding insulin for use in the treatment and / or prevention of neuroinflammation, neurodegeneration and / or cognitive decline, or a disease or condition associated therewith.

The present invention relates to a peptide having anti-obesity and anti-diabetes activities and uses thereof. The peptide of the present invention increases the expression of insulin genes and genes of PDX1 and GLP1R involved in insulin secretion, increases the secretion of insulin itself, and increases the expression levels of phospho-CREB and POMC factors associated with satiety signaling. In addition, the peptide of the present invention exhibits anti-obesity activity. Therefore, the peptide of the present invention can be used for treating, preventing, and alleviating obesity or diabetes, and can be advantageously used for lowering blood glucose levels of a person in need of blood glucose control.